[go: up one dir, main page]

DK1278540T3 - Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose - Google Patents

Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose

Info

Publication number
DK1278540T3
DK1278540T3 DK01945064T DK01945064T DK1278540T3 DK 1278540 T3 DK1278540 T3 DK 1278540T3 DK 01945064 T DK01945064 T DK 01945064T DK 01945064 T DK01945064 T DK 01945064T DK 1278540 T3 DK1278540 T3 DK 1278540T3
Authority
DK
Denmark
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Application number
DK01945064T
Other languages
English (en)
Inventor
Yolande Chvatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Serono Lab
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab, Inst Nat Sante Rech Med filed Critical Serono Lab
Application granted granted Critical
Publication of DK1278540T3 publication Critical patent/DK1278540T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK01945064T 2000-05-05 2001-04-30 Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose DK1278540T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
DK1278540T3 true DK1278540T3 (da) 2008-07-21

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01945064T DK1278540T3 (da) 2000-05-05 2001-04-30 Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose

Country Status (32)

Country Link
US (1) US20040076628A1 (da)
EP (1) EP1278540B1 (da)
JP (1) JP5122053B2 (da)
KR (2) KR100798545B1 (da)
CN (2) CN1841066B (da)
AR (1) AR035640A1 (da)
AT (1) ATE395075T1 (da)
AU (2) AU2001267390B2 (da)
BG (1) BG65881B1 (da)
BR (1) BRPI0110506B8 (da)
CA (1) CA2407895C (da)
CY (1) CY1110385T1 (da)
CZ (1) CZ300792B6 (da)
DE (1) DE60134009D1 (da)
DK (1) DK1278540T3 (da)
EA (2) EA005410B1 (da)
EE (1) EE05056B1 (da)
ES (1) ES2305082T3 (da)
HR (1) HRP20020828A2 (da)
HU (1) HU229375B1 (da)
IL (2) IL152567A0 (da)
ME (1) ME00554B (da)
MX (1) MXPA02010895A (da)
NO (1) NO329821B1 (da)
PL (1) PL209371B1 (da)
PT (1) PT1278540E (da)
RS (1) RS50926B (da)
SI (1) SI1278540T1 (da)
SK (1) SK287761B6 (da)
UA (2) UA87658C2 (da)
WO (1) WO2001085201A2 (da)
ZA (1) ZA200208228B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0108188A (pt) * 2000-02-10 2003-02-25 Abbott Lab Anticorpos que se ligam a interleucina-18 humana e métodos de produção e uso
EP1355668B1 (en) * 2001-01-29 2007-12-12 Laboratoires Serono SA Use of il-18 inhibitors for the treatment and/or prevention of heart disease
ES2617084T3 (es) * 2001-05-25 2017-06-15 Ares Trading S.A. Uso de inhibidores de IL-18 para tratar o prevenir lesiones en el SNC
US6797727B2 (en) 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
MXPA04009135A (es) 2002-03-22 2004-12-07 Applied Research Systems Uso de inhibidores de il-18 para el tratamiento y/o prevencion de enfermedades vasculares perifericas.
MXPA05009608A (es) * 2003-03-11 2006-03-21 Applied Research Systems Vectores de expresion que comprenden el promotor mcmv ie2.
PT1622939E (pt) 2003-05-13 2012-03-28 Merck Serono Sa Variantes ativas da proteína de ligação à il-18 e suas utilizações médicas
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP1755642B1 (en) * 2004-04-15 2010-01-13 Athera Biotechnologies Ab Annexin v for preventing plaque rupture
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
ATE517917T1 (de) 2005-06-03 2011-08-15 Ares Trading Sa Herstellung eines rekombinanten il-18-bindenden proteins
HRP20110948T1 (hr) 2005-06-10 2012-01-31 Ares Trading S.A. Postupak za pročišćavanje il-18 vezujućeg proteina
RU2013110874A (ru) 2010-08-25 2014-09-27 Ф.Хоффманн-Ля Рош Аг Антитела против il-18r1 и их применения
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
EP3041864B1 (en) 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
KR102511343B1 (ko) 2015-03-05 2023-03-17 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ) 및 항체
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein

Also Published As

Publication number Publication date
MEP64008A (en) 2011-12-20
AR035640A1 (es) 2004-06-23
AU2001267390B2 (en) 2005-09-22
CN1841066A (zh) 2006-10-04
EE200200620A (et) 2004-06-15
EE05056B1 (et) 2008-08-15
AU6739001A (en) 2001-11-20
IL152567A0 (en) 2003-05-29
CN1250286C (zh) 2006-04-12
HUP0301991A2 (hu) 2003-09-29
JP2003532685A (ja) 2003-11-05
EA007014B1 (ru) 2006-06-30
PL209371B1 (pl) 2011-08-31
EA200201175A1 (ru) 2003-04-24
JP5122053B2 (ja) 2013-01-16
UA78492C2 (en) 2007-04-10
PL365697A1 (en) 2005-01-10
MXPA02010895A (es) 2003-03-27
ATE395075T1 (de) 2008-05-15
RS50926B (sr) 2010-08-31
SK287761B6 (en) 2011-09-05
CZ300792B6 (cs) 2009-08-12
SI1278540T1 (sl) 2008-10-31
US20040076628A1 (en) 2004-04-22
WO2001085201A3 (en) 2002-05-10
UA87658C2 (uk) 2009-08-10
SK15562002A3 (sk) 2003-05-02
YU82602A (sh) 2006-01-16
HK1094909A1 (en) 2007-04-13
KR100798545B1 (ko) 2008-01-28
EP1278540B1 (en) 2008-05-14
ME00554B (me) 2012-03-20
CA2407895C (en) 2012-12-18
CY1110385T1 (el) 2015-04-29
CN1841066B (zh) 2012-08-29
WO2001085201A2 (en) 2001-11-15
BR0110506A (pt) 2003-04-01
BRPI0110506B1 (pt) 2015-05-19
KR20070073989A (ko) 2007-07-10
HRP20020828A2 (en) 2004-12-31
BG65881B1 (bg) 2010-04-30
HU229375B1 (en) 2013-11-28
CA2407895A1 (en) 2001-11-15
BG107218A (bg) 2003-06-30
PT1278540E (pt) 2008-07-03
ES2305082T3 (es) 2008-11-01
ZA200208228B (en) 2005-07-27
NO20025307D0 (no) 2002-11-05
CN1434722A (zh) 2003-08-06
IL152567A (en) 2010-12-30
HUP0301991A3 (en) 2006-11-28
EA005410B1 (ru) 2005-02-24
HK1055681A1 (en) 2004-01-21
NO329821B1 (no) 2010-12-27
CZ20023644A3 (cs) 2003-03-12
EP1278540A2 (en) 2003-01-29
BRPI0110506B8 (pt) 2021-05-25
KR20030016254A (ko) 2003-02-26
NO20025307L (no) 2002-12-18
DE60134009D1 (de) 2008-06-26
EA200401183A1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
DK1278540T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose
NO20032668L (no) Gyraseinhibitorer og anvendelser derav
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
IS6700A (is) Meðferðarblanda CETP hindra og atórvastatíns
NO20020343L (no) Kaspase-inhibitorer og anvendelse derav
NO20015274L (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
DK1726658T3 (da) Fremgangsmåde til fremstilling af dihydroxyestere og derivater deraf
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
IS7003A (is) Arómatisk súlfonhýdroxýamöt og notkun þeirra til tálmunar próteasa
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1337547T3 (da) Nuklease-baseret fremgangsmåde til detektion og kvantificering af oligonukleotider
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
PT1274700E (pt) Di-hidrobenzopiranos di-hidrobenzotiopiranos e tetra-hidroquinolinas para o tratamento de afeccoes mediadas por cox-2
DE60223540D1 (de) Mundschutz und mundschutzfolie
DK1079818T3 (da) Præparat omfattende IL-18 og topotecan til behandling og/eller forhindring af cancer
DK1456377T3 (da) Syn3-sammensætninger og fremgangsmåder
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
NO20011176D0 (no) FremgangsmÕte og anordning ved mær
DK1307761T3 (da) Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat